Oxeltis

Oxeltis and academic partners receive grant funding worth nearly €800,000 to develop antiviral for Bunyaviricetes 

France’s National Research Agency (ANR) and Defense Innovation Agency (AID) will finance BUNYANTIVIR project to introduce novel therapeutic approach for Bunyaviricetes class of human pathogenic viruses found in tropical and subtropical regions 25 June 2025 -- Montpellier, France -- Oxeltis, a CRO specialized in medicinal chemistry and fine organic chemistry for custom synthesis, today announces...
Cap Gamma, 1682 rue de la Valsière, BP 7247 34086 Montpellier Cedex 4 – France

+33 (0)499 235 036